On December 22, 2021 Helsinn Healthcare SA ("Helsinn"), a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets and strong track-record of commercial execution, and Juniper Biologics Pte Ltd ("Juniper"), a science-led healthcare company focused on researching, developing and commercializing novel therapies, reported the signing of exclusive distribution, license and supply agreements for Aloxi, Onicit, Paloxi, Akynzeo (IV and oral formulations) and anamorelin (INN) (Press release, Juniper Biologics, DEC 22, 2021, View Source [SID1234615017]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Under the terms of the agreements, Helsinn has granted Juniper exclusive licenses to register, import, distribute, promote, market and sell these products in Australia, New Zealand, Southeast Asia, and certain markets in Middle East and Africa.
Approved products:
Aloxi, Onicit and Paloxi (Palonosetron hydrochloride, IV, 25 mg as Palonosetron) for the prevention of chemotherapy induced nausea and vomiting (CINV)
Aloxi and Onicit (Palonosetron hydrochloride, IV, 075 mg as Palonosetron) for the prevention of post-operative nausea and vomiting (PONV)
Aloxi (Palonosetron hydrochloride, oral, 5 mg as Palonosetron) for the prevention of CINV
Akynzeo (Netupitant and Palonosetron hydrochloride, oral and Fosnetupitant and Palonosetron hydrochloride, IV) for the prevention of CINV
Product[s] under development:
Anamorelin (INN), an investigational, is a selective, novel, orally active ghrelin receptor agonist being developed for the treatment of malignancy-associated weight loss and anorexia in non-small cell lung cancer patients. Ghrelin is an endogenous peptide primarily secreted by the stomach. Upon binding to its receptor, ghrelin stimulates multiple pathways in the positive regulation of body weight, muscle mass, appetite and metabolism.
Riccardo Braglia, Helsinn Group Vice Chairman and CEO, commented:
"This agreement with Juniper Biologics further secures access to Helsinn’s supportive care products for those patients in real need in these important markets. We are pleased to be partnering with Juniper Biologics and are happy to share the future growth based on their top management vast knowledge in commercialization of novel therapies in these markets. We would like to always make a difference in the lives of many patients living with cancer."
Raman Singh, CEO of Juniper Biologics, commented: "Juniper Biologics was founded on a vision to provide the next generation of life-changing therapies to address unmet patient needs. Our partnership with the Helsinn Group with their excellence in innovation and cancer supportive care, helps us further this goal and is an important extension of our commitment to increase access to break-through medicines and to offer relief to patients suffering with cancer."
About Aloxi, Onicit and Paloxi
The exact therapeutic indication may be different in each country. Please consult the official approved product information in your country.
About Akynzeo
The exact therapeutic indication may be different in each country. Please consult the official approved product information in your country.